Based on the previous studies identifying the role of IGF2BP2 in various cancer types and our analysis of both primary prostate and CRPC patient samples, we postulated that the upregulation of IGF2BP2 might be linked to CRPC progression and enzalutamide resistance. This evidence concerns the gene IGF2BP2 and cancer.